Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab plus Vemurafenib and Cobimetinib in Advanced Melanoma
NCT02818023Phase 1Terminated
- Start
- Jul 2016
- Primary completion
- Jun 2019
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pembrolizumab in melanoma. Primary endpoint: Percentage of participants that experience a dose-limiting toxicity up to 2 years. Started Jul 2016; status: terminated.
02
Drugs
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT02818023.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02818023.